Primary Open Angle Glaucoma (POAG)NCT07119905
Association Between Matrix Metalloproteinase-9 Gene Polymorphism and Susceptibility to Primary Open Angle Glaucoma Patients in Sohag University Hospital
An observational study of Primary Open Angle Glaucoma (POAG), run by Sohag University at 1 site in Egypt.
Trial summary
The goal of this observational study is to investigate the potential association between MMP-9 gene polymorphism and susceptibility to Primary Open Angle Glaucoma development in Egyptian patients The main question it aims to Read more about this study
- Who is it for?
- Ages 30 years and olderHealthy volunteers can take part
- Conditions the study is for
- Primary Open Angle Glaucoma (POAG)
- What is being tested?
- genotyping assay by polymerase chain reaction
- How many people
- 80 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jun 2026to 1 Feb 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients with Primary Open Angle Glaucoma in Department of ophthalmology in Sohag University Hospitals and healthy controls of matched age and sex
Who may be able to join
- Men and women older than 30 years
- Primary open angle glaucoma as evidenced from characteristic visual field loss and optic disc cupping (POAG group)
- Healthy subjects matched by age, sex and ethnicity to the POAG patients group (control group)
Who cannot join
- Exfoliation glaucoma, pigmentary glaucoma
- History of acute angle closure
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site
Sohag University Hosipital
Sohag, Sohag Governorate, 82525
Magdy Mohamed Amin El Kady, Professor, ( 093 ) 4602963, portal@med.sohag.edu.eg
About this study
The goal of this observational study is to investigate the potential association between MMP-9 gene polymorphism and susceptibility to Primary Open Angle Glaucoma development in Egyptian patients The main question it aims to
Read the detailed description
Glaucoma is the second most common cause of blindness worldwide. Glaucoma is a progressive optic neuropathy, characterized by a specific loss of retinal nerve fibres and ganglion cells, gradual decrease of the visual field, and vertical elongation of optic disc cupping. Glaucoma causes a slow loss of vision in the centre of the field of view as well as in the periphery. This results in delays in the diagnosis and treatment, and it is likely that the glaucoma may not be diagnosed until the disease has progressed to a moderate or severe level, at which point significant vision loss will have already taken place
POAG is the most common type of glaucoma that is characterized by specific glaucomatous retinal, optic nerve, and clinical findings without a clear secondary cause.
POAG is a progressive optic neuropathy characterized by loss of ganglion cells and deterioration of the visual field in eyes with gonioscopically open angles, either with or without increased intraocular pressure (IOP).
Matrix Metalloproteinase-9 gene Matrix metalloproteinases (MMPs) are a kind of calcium-zinc ion-dependent proteolytic enzyme involved in a variety of cellular processes. MMPs are well known for their ability to degrade the extracellular matrix (ECM) and are involved in several intracellular mechanisms from cell differentiation, proliferation, and angiogenesis to apoptosis.
The MMP genes were suggested to play an important role in the development of various glaucoma types, MMPs are important regulators of the aqueous humor outflow from the eye anterior chamber and therefore significantly affect intraocular pressure. Patients with diagnosed POAG have an altered MMPs level in the aqueous humor.
Several studies have been conducted to analyze polymorphic variants of the MMP for their possible contribution to POAG, Several loci of the MMP genes (rs3918242, rs3918249, rs17576 matrix metalloproteinase-9 were associated with POAG.
- Conditions
- Primary Open Angle Glaucoma (POAG)
- Being tested
- genotyping assay by polymerase chain reaction
- Keywords
- Primary Open Angle Glaucoma, POAG, Gene Polymorphism, MMP-9, Matrix Metalloproteinase-9 Gene Polymorphism
- Medical subject headings
- Glaucoma, Open-Angle
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
genotyping assay by polymerase chain reactionGenetic
Blood sample will be obtained from all participants by withdrawing 3 mL of blood via venipuncture in ethylenediaminetetraacetic acid tube.
Thereafter, DNA extraction will be obtained after centrifugation to be used for genotyping assay of MMP-9 gene with polymerase chain reaction
| Study group | Role | What they receive |
|---|---|---|
| Control Group | Normal healthy volunteers aged > 30 years Receives: Genetic: genotyping assay by polymerase chain reaction | |
| Experimental Group | Patients aged >30 years and diagnosed with Primary Open Angle Glaucoma Receives: Genetic: genotyping assay by polymerase chain reaction |
What is being measured
The primary outcome is the main question the study is designed to answer.
Matrix metalloproteinase-9 gene polymorphism
Matrix metalloproteinase-9 gene polymorphism by polymerase chain reaction
Measured: 14 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Aug 2025
- Study start1 Jun 2026 (estimated)
- Primary completion1 Jan 2027 (estimated)
- Study completion1 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Primary Open Angle Glaucoma (POAG)Studies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Thomas Talaat Nageh, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07119905
- Sponsor's protocol ID
- Soh-Med--25-7-16MS
- Status last verified
- Aug 2025
- First submitted
- 2 Aug 2025
- Last updated
- 13 Aug 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Grzybowski A, Och M, Kanclerz P, Leffler C, Moraes CG. Primary Open Angle Glaucoma and Vascular Risk Factors: A Review of Population Based Studies from 1990 to 2019. J Clin Med. 2020 Mar 11;9(3):761. doi: 10.3390/jcm9030761.
PubMed 32168880Liu Y, Allingham RR. Major review: Molecular genetics of primary open-angle glaucoma. Exp Eye Res. 2017 Jul;160:62-84. doi: 10.1016/j.exer.2017.05.002. Epub 2017 May 10.
PubMed 28499933Zhao F, Fan Z, Huang X. Role of matrix metalloproteinase-9 gene polymorphisms in glaucoma: A hospital-based study in Chinese patients. J Clin Lab Anal. 2020 Mar;34(3):e23105. doi: 10.1002/jcla.23105. Epub 2019 Nov 12.
PubMed 31713905
Study at a glance
From the registry record, last updated by the sponsor on 13 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Association Between Matrix Metalloproteinase-9 Gene Polymorphism and Susceptibility to Primary Open Angle Glaucoma Patients in Sohag University Hospital
- ClinicalTrials.gov ID
- NCT07119905
- Acronym / sponsor ID
- Soh-Med--25-7-16MS
- Conditions
- Primary Open Angle Glaucoma (POAG)
- Keywords
- Primary Open Angle Glaucoma, POAG, Gene Polymorphism, MMP-9, Matrix Metalloproteinase-9 Gene Polymorphism
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Jun 2026 (estimated)
- Primary completion
- 1 Jan 2027 (estimated)
- Study completion
- 1 Feb 2027 (estimated)
- First posted
- 13 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to investigate the potential association between MMP-9 gene polymorphism and susceptibility to Primary Open Angle Glaucoma development in Egyptian patients The main question it aims to
Detailed description
Glaucoma is the second most common cause of blindness worldwide. Glaucoma is a progressive optic neuropathy, characterized by a specific loss of retinal nerve fibres and ganglion cells, gradual decrease of the visual field, and vertical elongation of optic disc cupping. Glaucoma causes a slow loss of vision in the centre of the field of view as well as in the periphery. This results in delays in the diagnosis and treatment, and it is likely that the glaucoma may not be diagnosed until the disease has progressed to a moderate or severe level, at which point significant vision loss will have already taken place
POAG is the most common type of glaucoma that is characterized by specific glaucomatous retinal, optic nerve, and clinical findings without a clear secondary cause.
POAG is a progressive optic neuropathy characterized by loss of ganglion cells and deterioration of the visual field in eyes with gonioscopically open angles, either with or without increased intraocular pressure (IOP).
Matrix Metalloproteinase-9 gene Matrix metalloproteinases (MMPs) are a kind of calcium-zinc ion-dependent proteolytic enzyme involved in a variety of cellular processes. MMPs are well known for their ability to degrade the extracellular matrix (ECM) and are involved in several intracellular mechanisms from cell differentiation, proliferation, and angiogenesis to apoptosis.
The MMP genes were suggested to play an important role in the development of various glaucoma types, MMPs are important regulators of the aqueous humor outflow from the eye anterior chamber and therefore significantly affect intraocular pressure. Patients with diagnosed POAG have an altered MMPs level in the aqueous humor.
Several studies have been conducted to analyze polymorphic variants of the MMP for their possible contribution to POAG, Several loci of the MMP genes (rs3918242, rs3918249, rs17576 matrix metalloproteinase-9 were associated with POAG.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control Group | – | Genetic: genotyping assay by polymerase chain reactionNormal healthy volunteers aged > 30 years |
| Experimental Group | – | Genetic: genotyping assay by polymerase chain reactionPatients aged >30 years and diagnosed with Primary Open Angle Glaucoma |
Who may qualify
- Ages
- 30 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with Primary Open Angle Glaucoma in Department of ophthalmology in Sohag University Hospitals and healthy controls of matched age and sex
Key inclusion criteria (3 listed)
- Men and women older than 30 years
- Primary open angle glaucoma as evidenced from characteristic visual field loss and optic disc cupping (POAG group)
- Healthy subjects matched by age, sex and ethnicity to the POAG patients group (control group)
Key exclusion criteria (2 listed)
- Exfoliation glaucoma, pigmentary glaucoma
- History of acute angle closure
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| genotyping assay by polymerase chain reactionBlood sample will be obtained from all participants by withdrawing 3 mL of blood via venipuncture in ethylenediaminetetraacetic acid tube. Thereafter, DNA extraction will be obtained after centrifugation to be used for genotyping assay of MMP-9 gene with polymerase chain reaction | Genetic | Control Group, Experimental Group |
Primary outcome
Matrix metalloproteinase-9 gene polymorphism
Time frame: 14 months
Matrix metalloproteinase-9 gene polymorphism by polymerase chain reaction
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Aug 2025.
- Background: PubMed 32168880Grzybowski A, Och M, Kanclerz P, Leffler C, Moraes CG. Primary Open Angle Glaucoma and Vascular Risk Factors: A Review of Population Based Studies from 1990 to 2019. J Clin Med. 2020 Mar 11;9(3):761. doi: 10.3390/jcm9030761.
- Background: PubMed 28499933Liu Y, Allingham RR. Major review: Molecular genetics of primary open-angle glaucoma. Exp Eye Res. 2017 Jul;160:62-84. doi: 10.1016/j.exer.2017.05.002. Epub 2017 May 10.
- Background: PubMed 31713905Zhao F, Fan Z, Huang X. Role of matrix metalloproteinase-9 gene polymorphisms in glaucoma: A hospital-based study in Chinese patients. J Clin Lab Anal. 2020 Mar;34(3):e23105. doi: 10.1002/jcla.23105. Epub 2019 Nov 12.
- Individual participant dataSharing planned: Undecided
Related trials for Primary Open Angle Glaucoma (POAG)
RecruitingPhase 2
A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.
Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Recruiting
The Acute Effect of Exercise Type And Timing on Ambulatory Blood Pressure and Intra-Ocular Pressure in Individuals With Glaucoma (The ACHIEVE-project).
Glaucoma Open-Angle Primary, Hypertension
RecruitingObservational study
PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group
Primary Open Angle Glaucoma
Active, not recruitingObservational study
Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults
Primary Open Angle Glaucoma
Active, not recruitingObservational study
Impact of Glaucoma and Visual Field Loss on Life Space
Primary Open-angle Glaucoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Primary Open Angle Glaucoma (POAG), run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 13 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Thomas Talaat Nageh, Demonstrator (20 1276890796, thomas.talaat@med.sohag.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Matrix metalloproteinase-9 gene polymorphism (time frame: 14 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07119905, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2025.